TAK 041
Alternative Names: NBI 1065846; NBI-846; TAK-041Latest Information Update: 26 Sep 2023
Price :
$50 *
At a glance
- Originator Takeda
- Developer Neurocrine Biosciences; Takeda
- Class Antipsychotics; Nootropics
- Mechanism of Action GPR139 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cognition disorders; Major depressive disorder; Schizophrenia
Most Recent Events
- 07 Sep 2023 Neurocrine Biosciences completes the phase III TERPSIS trial in Major-depressive-disorder in USA and Puerto rico (NCT05165394)
- 30 Jun 2023 Discontinued - Phase-I for Cognition disorders (In volunteers) in United Kingdom (PO) (Takeda pipeline; February 2024)
- 30 Jun 2023 Discontinued - Phase-I for Cognition disorders (In volunteers) in USA (PO) (Takeda pipeline; February 2024)